
AACR
From CRISPR technology and single-cell spatial analysis to targeting KRAS-G12C and BRAF, WuXi AppTec is proud to be presenting 10 posters at this year's AACR annual meeting. As a global leader in supporting cancer drug discovery programs, WuXi AppTec offers a comprehensive platform of services, including drug-resistant CDX/PDX tumor models, antibody-drug conjugates, and CAR-T cell therapy.
Our scientists welcome the opportunity to meet with you during this prestigious conference. Visit us at Booth 1427 to get your oncology-related questions answered by one of our experts. For a dedicated meeting time, you can also pre-arrange a one-on-one discussion by completing this brief form, or contacting us at discoveryservices@wuxiapptec.com
WuXi AppTec Poster Presentations:
Integrated platform enables KRAS-targeted drug discovery |
Integrated single-cell and spatial analysis reveal the mechanism of KRASG12C inhibitor AMG510 in HSC-humanized NOG-EXL model |
Safety assessment and pharmacodynamic evaluation of therapeutic cytokines in non-human primates |
Therapeutic potential of polatuzumab vedotin for the treatment of diffuse large B-cell lymphoma |
A tailored platform enables BRAF-targeted drug discovery and precision medicine |
Developing cancer cell based in vitro and in vivo models with CRISPR-mediated knock-in technology for anti-tumor drug discovery |
Comparison of two DTH models for T cell-mediated immunity in preclinical screening |
Multi-plex cytokine profiling for mice on Bleomycin-induced systemic sclerosis model |
Blocking autophagy ameliorates the severity of ConA-induced autoimmune hepatitis in mice |
CDX model-based genome-scale CRISPR KO screens for modulators of KRAS (G12C) inhibitor sensitivity |